Kornimate/medical-research-clean huggingface dataset:
the comparison of hyajoint plus and hyalgan hyaluronan supplement for knee osteoarthritis pain

Conditions: Osteoarthritis, Knee

Summary: the aim of this study was to compare single injection hyajoint plus synovial fluid supplement used on the single and repeat treatment of knee osteoarthritis that has the same safety and effectiveness as three-injection hyaluronan, hyalgan.

the study was a random, evaluator-blinded, controlled, single center clinical trial. recruiting patients who have been suffered from the osteoarthritis pain under conventional nonpharmacologic therapy or analgesics for a long time and randomly divided into two groups, hyajoint plus or hyalgan group, when the inclusion criteria was met and the inform consent was obtained. they were followed for 56 weeks including visits at 4, 12, 26, 39, and 52 weeks post-treatment for the safety and effectiveness evaluation. after complete 52-week visit, subjects would received hyajoint plus on the target knee. these subjects were followed for 4 weeks to assess the safety of repeat treatment or cross reactions of the use from three-injections to single-injection hyaluronan treatment. the primary endpoints were the incidence of any adverse events during the study, as well as the objective assessment of pain visual analog scale at baseline and every visit.

Eligibility criteria:
inclusion criteria: * symptomatic knee osteoarthritis for at least 6 months despite nonoperative treatment and/or physical therapy * average knee pain score ≧ 30 mm on a 100-mm vas * kellgren-lawrence grade 2 or 3 knee osteoarthritis based on radiographs taken within previous 6 months 18 * if the vas pain score of the contralateral knee with radiographic evidence of bilateral knee osteoarthritis was \< 30 mm exclusion criteria: * hip oa * kellgren-lawrence grade 4 on target knee * clinical apparent active symptoms like infections * intra-articular injections of hyaluronan within the past 6 months * previous orthopaedic surgery on spine or lower limb * intra-articular injections of steroid type drugs within the past 3 months * diagnosed as lupus erythematosus, rheumatoid arthritis, hemiparesis, neoplasm or received hemodialysis * known allergy to avian proteins or hyaluronic acid products * women ascertained or suspected pregnancy or lactating

Keywords: hyaluronan synovial fluid supplement
effect of combined lumbar traction and repetitive back extension exercise on h-reflex in lumbosacral radiculopathy

Conditions: Lumbosacral Radiculopathy; McKenzie Derangement Syndrome

Summary: the aim of the study is to investigate the effect of performing combined lumbar traction and repeated back extension exercise (mckenzie) on soleus h-reflex, pain, and disability in patients with lumbosacral radiculopathy. the main question that it aims to answer is: does the combination of lumbar traction and back extension exercise (mckenzie) improves soleus h-reflex, pain, and function in patient with lumbosacral radiculopathy? participants will be randomized into 2 groups: one group will include repeated back extension exercise (mckenzie approach) without mechanical traction and the other group will include the same but in combination with mechanical traction.

repeated back extension exercises as described by mckenzie from prone position has been widely suggested for patients with lumbosacral radiculopathy (lsr). it has been reported to decrease radicular symptoms which could be due to the decompression effect of this exercise on the compromised nerve root. moreover, mechanical traction have a debatable effect on lumbosacral patients with little evidence that supports its effectiveness. thus, the investigators hypothesize that performing a combination of lumbar traction and repeated back extension exercise will improve the soleus h-reflex, pain, and function of lumbosacral radiculopathy patients.

Eligibility criteria:
inclusion criteria: 1. patient with chronic unilateral lumbosacral radiculopathy (more than 3 months duration) 2. age:35- 60 years 3. both male and female 4. people with l5-s1 postero-lateral disc herniation or protrusion. 5. people with positive straight leg raise exclusion criteria: 1. subjects with lumbosacral surgery. 2. subjects with stenosis or scoliosis. 3. subjects with cardiac problem or cancer. 4. subjects with peripheral neuropathy. 5. subjects with upper motor neuron injury.

Keywords: h-reflex radiculopathy mckenzie lumbar traction
impact study on cerecare compression garments in the treatment of ehlers-danlos syndromes

Conditions: Eds, Unspecified Type

Summary: eds (ehlers-danlos syndromes) form a heterogeneous group of hereditary connective tissue pathologies, which present a characteristic triad: cutaneous hyperelasticity, articular hyperlaxity and connective tissue fragility. the innumerable sprains and dislocations of all the joints require recurrent immobilizations and are responsible for a musculoskeletal handicap, chronic pains and a great fatigability, resounding on the quality of life of the patient. the use of custom-made compression garments seems to provide relief from pain, especially nociceptive pain and in stabilizing joints by proprioceptive effect. the sedcare study is an observational monocentric, non-comparative study. 76 patients will be followed in this study for 2 years during which they will wear compression custom-made garments (cerecare®).the main objective of this study is to demonstrate the effectiveness of pressure garments cerecare in the eds, especially in terms of joint pain.


Eligibility criteria:
inclusion criteria: * ehlers-danlos syndrome diagnosis confirmed by a medical specialist, according to the new diagnostic criteria of 2017, * articular hyperlaxity, * have not used compression garments for at least 1 year, * without expected body weight change within 6 months, * having agreed to participate in the study exclusion criteria: * presenting a known allergy to the components of compression garments, * presenting acute and unusual pain, not medically controlled, * pregnant woman, * participating simultaneously with another study or having recently participated in another study for which the exclusion period would not be completed.
eccentric training with or without elbow brace for epicondylitis

Conditions: Epicondylitis; Tendinopathy; Pain

Summary: lateral epicondylitis is a painful overuse condition also described as lateral elbow tendinopathy. as at the achilles tendon or the patella tendon, lateral elbow tendinopathy has striking clinically and histologically similarities. as such, neovascularisation closely related to pain-mediating fibers are encountered. eccentric painful exercise is of clinical use in achilles and patella tendinopathy. we sought to evaluate the clinical effect of a painful eccentric training (supination and pronation) with or without a orthopedic elbow brace in lateral epicondylitis.

two study arms are planned with both groups performed a home-based eccentric training using a thera-band flex-bar device. supination and pronation are performed with each position on hold for 2s with 15 repetitions. this is repeated in three sets of 15 repetitions each twice daily. in other words, 6x15 repetitions of supination and pronation per day are suggested in the eccentric training using the thera-band flex-bar. the combination group performs the same eccentric training. in addition, patients wear a orthopedic elbow brace (epi-hit) in order to overcome the elbow pain. this is a clinical trial, thus pain reduction on a visual analogue scale is the primary outcome parameter. evaluation will be performed after 12 weeks of intervention.

Eligibility criteria:
inclusion criteria: * lateral elbow tendinopathy * 18-80 years informed consent exclusion criteria: * no elbow tendinopathy \ 80 years no informed consent

Keywords: pain elbow tendinopathy
changes in brown adipose tissue activity in men receiving androgen deprivation therapy for prostate cancer

Conditions: Prostate Cancer

Summary: androgen deprivation therapy (adt) is considered standard of care for prostate cancer. however, changes in the patients metabolism are usually seen as a result of hormone therapy. these changes include increased fat mass, decreased lean mass, weight gain, high blood cholesterol, increased incidence of diabetes, and possibly increased incidence of cardiac events such as heart attack. the researchers of this trial would like to learn if these change in body mass are affected by the presence of brown fat in the body. brown fat is made up of fat cells that are stored in the body and generate heat to control body temperature. levels of brown fat are at the highest in newborn babies and decrease over time into adulthood. the researchers of this trial would like to learn more about these changes in metabolism during prostate cancer treatment by studying the changes in brown fat during the first 12 months of hormone therapy.

* participants will be asked to come into the clinic for additional visits before they begin hormone therapy. the following procedures will be performed: cold-activated pet/ct scan; body composition dxa scan; blood tests, questionnaires and abdominal fat biopsy. * during hormone therapy, the participant will return to the clinical once after 3 months, and again after 6 months, to draw blood for laboratory tests. * after 12 months of hormone therapy, the participant will return to teh clinic to repeat the following procedures: cold-activated pet/ct scan; body composition dxa scan; blood tests; questionnaires and abdominal fat biopsy.

Eligibility criteria:
inclusion criteria: * adenocarcinoma of the prostate * scheduled to initiate gnrh agonist or antagonist treatment with an intended treatment duration of 12 months or greater * ecog performance status of 0 or 1 * ability to understand and the willingness to sign a written informed consent * 65 years of age or younger exclusion criteria: * diagnosis of diabetes * ongoing corticosteroid use * gnrh agonist or antagonist treatment within the last 2 years * ongoing beta-blocker use * body mass index of greater than 30

Keywords: brown adipose tissue androgen deprivation therapy
impact of ceftriaxone and/or fluoroquinolone (fq) treatment on the gut microbiota of hospitalized patients.

Conditions: Bacterial Infections

Summary: observational study of the effects of antibiotics on commensal flora. realization of stool samples and nasal swabs before and after antibiotic therapy.

the emergence of resistance to fluoroquinolone (fq) and is a major problem worldwide. the commensal flora is the main reservoir for antibiotic resistance. understanding the factors (environmental, patient-related, dosis-related, drug-related...) involved in the emergence of resistance to fluoroquinolones in the commensal flora of patients treated with a fq, may help prevent it and preserve the efficiency of these important antibiotics. samples of digestive flora will be collected from hospitalized patients before receiving a fq or ceftriaxone, at the end of the treatment and 3 month after the end of treatment. clinical data will be collected.

Eligibility criteria:
inclusion criteria for the patients treated with antibiotics * adult patient hospitalized in a participating ward of the hospital for an expected duration of more than 24 hours. * treatment by ceftriaxone and / or a fluoroquinolone started by the attending physicians during hospitalization. * no hospitalization or stay in nursing home in the previous three months. * no use of antibiotics in the last 3 months * not receiving other antibiotics than ceftriaxone or fq * informed consent inclusion criteria for the patients in the reference group * adult patient hospitalized in a participating ward of the hospital for an expected duration of more than 24 hours. * not receiving any antibiotic and not expected to receive any during hospitalization * no hospitalization or stay in nursing home in the previous three months. * no use of antibiotics in the last 3 months * informed consent exclusion criteria * pregnant or nursing women * patient who underwent colectomy or suffering from chronic intestinal disease (inflammatory intestinal disease or short bowel syndrome) * patient who used a bowel preparation solution for colonoscopy during hospitalization or in the previous week. * protected adult patient (deputyship or guardianship)

Keywords: study of commensal flora fluoroquinolones
evaluation of gvhd damage on medullary mesenchymal stem cells

Conditions: Graft Vs Host Disease

Summary: spontaneous, multicenter, prospective, non-pharmacological study. at the diagnosis of acute or chronic gvhd after hsct, bone marrow cells will be analysed for msc content and properties. bone marrow aspirate will be performed according to usual clinical practise


Eligibility criteria:
inclusion criteria: * patients (children and adults) developing acute or chronic gvhd after hsct. * age 6 months- month-99 years, * landsky-karnofsky\> 70%, * acute or chronic gvhd needing further immunosuppressive treatment. exclusion criteria: * anything not included in the inclusion criteria.
impact of antiretroviral therapy on cardiac biomarkers

Conditions: HIV Infections

Summary: cardiovascular risk appears to be linked to some degree with inflammation. hiv medications have been linked with cardiovascular risk. in this study we will be measuring levels of chemicals in the body associated with inflammation before and after starting hiv medications in patients with hiv. we hope to understand what happens to these chemicals once a patient with hiv is started on these medications to understand their role in cardiovascular risk.

with the advent of antiretroviral therapy, death due to opportunistic diseases have seen a major decline among patients with hiv. however, several antiretroviral medications, in particular protease inhibitors (pi), have been associated with increased cardiovascular risk in large cohort studies. the role of inflammation in cardiovascular risk is currently being elucidated. high sensitivity c-reactive protein (hscrp) has been identified as a strong independent predictor of cardiovascular disease among healthy individuals in several large cohort studies. other inflammatory biomarkers such as serum amyloid a (saa) and interleukin-6 (il-6) have also been correlated with cardiovascular risk. among patients with hiv, studies have revealed inappropriate immune activation with increased pro-inflammatory cytokines such as il-6, il-10, interferon-γ (ifn- γ), and tumor necrosis factor-α (tnf-α). the effects of this immune dysregulation and the impact of antiretroviral therapy on the cytokines and biomarkers associated with cardiovascular risk remain to be delineated. objective: our aims are to characterize the levels of inflammatory biomarkers at the time of antiretroviral initiation, to define the time period over which the biomarkers change and stabilize, and to determine if the type of antiretroviral drug class used has an impact on the rate of alteration of these biomarkers. given the disparate cardiovascular risk between women and men of similar age groups, we will study the additional impact of gender on these biomarkers. we will also explore whether there is a correlation between change of cd4 t-lymphocyte counts and the response of the biomarkers.

Eligibility criteria:
inclusion criteria: * patients with a cd4 count between 200-400 planning on initiating antiretrovirals. exclusion criteria: * pregnancy, * recent discontinuation of an antiretroviral within the past 30 days, * active intravenous drug use, * acute febrile illness with temperature \> 100 f, * diagnosis or symptoms of acute infection within the past 30 days, * opportunistic infection or surgical procedure within the past 60 days, * myocardial infarction within the last 30 days, * renal disease (ckd stages 3-5), and * unstable liver disease.

Keywords: cardiovascular risk inflammatory biomarkers human immunodeficiency virus
vitamin a supplementation for extremely-low-birth-weight infants

Conditions: Infant, Newborn; Infant, Low Birth Weight; Infant, Small for Gestational Age; Infant, Premature; Bronchopulmonary Dysplasia; Respiration, Artificial; Respiratory Distress Syndrome, Newborn; Sepsis

Summary: this multi-site, randomized trial was conducted to determine the safety and effectiveness of a higher dose of vitamin a and determine if this would increase the rate of survival without bronchopulmonary dysplasia (bpd) and reduce the risk of sepsis. infants with birth weights from 401-1000g and who were on mechanical ventilation or supplemental oxygen at 24-96 hours of age were enrolled. subjects were randomized to either the vitamin a or a control group. infants in the vitamin a group were given a dose of 5000 iu (0.1 ml) intramuscularly on mondays, wednesdays, and fridays for four weeks. control infants received a sham procedure rather than placebo injections.

infants with extremely low birth weights (≤1,000 g) have low plasma and tissue concentrations of vitamin a, and vitamin a deficiency may predispose these infants to chronic lung disease. a meta-analysis of clinical trials of vitamin a supplementation for preterm infants revealed a 17% increase in the rate of survival without chronic lung disease, which approached statistical significance. this multi-site, randomized trial was conducted to determine the safety and effectiveness of a higher dose of vitamin a than that used in previous trials in extremely-low-birth-weight (elbw) infants. we hypothesized that vitamin a supplementation would increase the rate of survival without bronchopulmonary dysplasia and reduce the risk of sepsis. infants with birth weights from 401-1000g and who received mechanical ventilation or supplemental oxygen at 24-96 hours of age were enrolled. subjects were randomized to either the vitamin a or a control group. infants in the vitamin a group were given a dose of 5000 iu (0.1 ml) intramuscularly on mondays, wednesdays, and fridays for four weeks. control infants received a sham procedure rather than placebo injections. serum vitamin a was measured in a central laboratory at base line and at 28 days in the first 300 infants. on study day 28 (two to three days after the last treatment and immediately after a blood sample was collected), the relative dose-response was evaluated.

Eligibility criteria:
inclusion criteria: * infants wtih birth weights from 401-1,000g * receiving mechanical ventilation or supplemental oxygen at 24-96 hours of age exclusion criteria: * major congenital anomalies * congenital nonbacterial infection * infants diagnosed with a terminal illness (as indicated by a ph below 6.80 or by the presence of hypoxia with bradycardia for more than two hours) * infants who were to receive vitamin a in a parenteral fat emulsion or in doses exceeding recommendations for multivitamin preparations

Keywords: nichd neonatal research network extremely low birth weight (elbw) prematurity vitamin a chronic lung disease
prospective multicenter non-interventional study in patients with knee or hip osteoarthritis having a theraflex treatment

Conditions: Osteoarthritis

Summary: the main purpose of this study is to evaluate how a long-term treatment with theraflex during 64 weeks affects pain intensity in the affected knee or hip joint, the activity in daily living, the quality of life and patient satisfaction with treatment.

other information that is planned for evaluation in this study includes consumption of theraflex, intake of analgesics for joint pain relief and description of basic patient characteristics such as age, weight and body mass index and others.

Eligibility criteria:
inclusion criteria: * patients 45 to 75 years with hip or knee oa stage i to iii * patient started current treatment with theraflex not more than 2 weeks prior to inclusion into the study * personally signed and dated informed consent exclusion criteria: * patients participating in an investigational program with interventions outside of routine clinical practice * patients with hip or knee oa stage 0 or stage iv * patients who have both hip and knee oa and oa of any other location * contraindications for use of theraflex in accordance with approved label(known hypersensitivity, severe chronic renal failure) * females who are pregnant or breastfeeding * patients who completed a treatment with theraflex or another combination of gl+ ch less than 5 months before start of the current treatment * patients who completed intra-articular corticosteroids treatment in the last 3 months to exclusion criteria * patients who completed hyaluronic injections of the lower limbs in the last 6 months
inorganic pyrophosphate homeostasis (ppi) in pediatric chronic kidney disease

Conditions: Pyrophosphate, Fetuin A, IL1, IL6, TNFalpha, Control

Summary: the investigator aim to identify the role of inorganic pyrophosphate and other anti-calcifying molecules in vascular disease in children with chronic kidney disease, with a view to developing therapeutic approaches aimed at limiting the onset of vasculopathy.

the study of pro- and anti-calcifying molecules in children with chronic kidney disease will be carried out using dosages made on serum in comparison with the dosage of these same molecules in control children matched according to age and sex. without chronic kidney disease. an evaluation of vascular function by clinical (auscultation, palpation) and ultrasound techniques (measurement of intima-media thickness and measurement of pulse wave velocity) will also be carried out in children with chronic kidney disease and compared to norms of children without chronic kidney disease. these evaluations aim to improve understanding of the pathophysiology of vascular calcification and thus open up therapeutic perspectives in these children.

Eligibility criteria:
inclusion criteria: all groups : * minor patients (\<18 years) * patients of both sexes * informed patients and parents who have signed the informed consent form * patients affiliated to social security control group : - patients with no particular pathology undergoing surgery and receiving a preoperative check-up ckd groups : * patients on dialysis for more than 3 months, regardless of technique * kidney transplant patients * patients with ckd, whatever the cause exclusion criteria: * progressive cancer or kidney disease * treatments that may modify ppi concentration (e.g. bisphosphonates)

Keywords: pyrophosphate